Trials / Withdrawn
WithdrawnNCT00808626
Phase II Investigation of 99mTc-rBitistatin for Imaging Venous Thrombosis
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Temple University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
99mTc-rBitistatin is a radiolabeled polypeptide which is designed to stick to blood clots so that the blood clots can be detected by imaging. The purpose of this trial is to evaluate in patients the safety of 99mTc-rBitistatin and its ability to locate blood clots in the arms and legs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 99mTc-rBitistatin | Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours. |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2008-12-16
- Last updated
- 2015-05-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00808626. Inclusion in this directory is not an endorsement.